Specialized Applications

Specialized therapeutic applications and use cases for psychedelic mushrooms

End-of-Life Care

Using psychedelics to address anxiety, depression, and existential distress in terminal illness.

Palliative Care

Applications in palliative care settings for improving quality of life and reducing suffering.

Trauma Therapy

Trauma-informed approaches to using psychedelics for healing from trauma and PTSD.

Addiction Treatment

Evidence-based approaches to treating substance use disorders and behavioral addictions.

Couples Therapy

Using psychedelics in relationship therapy to improve communication and connection.

Clinical Focus & Guardrails

These applications demand higher safety, ethics, and professional oversight. Each linked page outlines screening, consent language, contraindications, and session protocols tailored to the population.

Core Safeguards

  • Medical and psychiatric screening with escalation pathways
  • Drug–drug interaction checks (SSRIs, SNRIs, MAOIs, lithium, stimulants)
  • Emergency response roles, equipment, and transfer agreements
  • Clear scope-of-practice boundaries for non-clinicians

Protocol Design

  • Session structure: preparation, dosing, acute support, integration
  • Validated measures: PHQ-9, GAD-7, PCL-5, MEQ30, pain scales
  • Documentation: consent, adverse events, dosage logs, follow-ups
  • Family/caregiver involvement and post-session safety plans

Current Evidence Landscape

Psilocybin-assisted therapy has moved from fringe interest to mainstream clinical science in under two decades. Below is a concise map of where the evidence currently sits for each specialised population.

End-of-Life & Palliative Care

Landmark Johns Hopkins and NYU trials (2016) demonstrated that a single high-dose psilocybin session produced sustained reductions in existential distress, depression, and death anxiety in patients with life-threatening cancer diagnoses — effects persisted at 6-month follow-up in the majority of participants. Phase 2 extensions and replication studies are underway globally.

Trauma & PTSD

Psilocybin is hypothesised to reduce fear-conditioned responding by temporarily flattening the cortical hierarchy, facilitating reprocessing of traumatic memories. Early-phase trials and open-label studies show promising reductions on PCL-5 and IES-R scales. Trauma-specific protocols require extended preparation and trauma-informed facilitation training.

Addiction Treatment

Matthew Johnson's tobacco cessation work at Johns Hopkins reported 80% abstinence at 6 months — far exceeding standard treatment benchmarks. Michael Bogenschutz's alcohol use disorder trial (NEJM, 2022) showed significant reductions in heavy drinking days. Both required robust psychotherapeutic scaffolding around the dosing sessions.

Cross-Cutting Safeguards

Screening Essentials

  • Personal and family history of psychosis, bipolar I, or schizophrenia — absolute contraindications
  • Active suicidal ideation with plan: defer until stabilised
  • Current medications: SSRIs, SNRIs, MAOIs, lithium all require evaluation and possible tapering under medical supervision
  • Cardiovascular conditions: psilocybin transiently elevates heart rate and blood pressure — cardiac clearance needed for high-risk cases
  • Validated measures pre-session: PHQ-9, GAD-7, PCL-5 (trauma), MEQ30 (mystical experience); repeat at 1, 4, and 12 weeks post

Session & Integration Framework

  • Preparation (2–4 sessions): Build therapeutic alliance, set intentions, explain the experience arc, establish a distress protocol
  • Dosing session (6–8 hours): Comfortable setting, eye shades, curated music; facilitators present but non-directive
  • Integration (minimum 3 sessions post-dose): Process content, consolidate insights, build relapse prevention plans
  • Family/caregiver briefing for end-of-life and palliative populations
  • Documentation: signed informed consent, adverse event log, dosage record, follow-up plan

Integration Playbooks

Population-specific approaches: grief processing for terminal illness, EMDR-adjacent trauma integration, addiction relapse prevention with motivational interviewing, and relational repair in couples contexts. Each linked page includes session-by-session integration prompts.

Ethics & Compliance

Consent templates, confidentiality boundaries, scope-of-practice guidance for non-clinicians, and mandatory reporting obligations. Operating within current legal frameworks varies substantially by jurisdiction — check local regulations before proceeding.

Couples Therapy Considerations

Dyadic sessions require additional screening (relationship power dynamics, history of domestic violence, individual stability). High-conflict couples are generally contraindicated. Separate individual integration sessions should precede and follow any joint session.

FAQ

  1. Can these be done without clinicians? Medical oversight is strongly recommended; end-of-life, trauma, and addiction applications may legally require licensed clinicians in regulated contexts.
  2. How is dosing adjusted for frail or elderly patients? Begin at the lower therapeutic threshold (15–20 mg synthetic psilocybin or ~2–3 g dried), extend monitoring windows, and coordinate clearance with medical teams managing concurrent conditions.
  3. What makes trauma work different from general psychedelic sessions? Trauma-informed facilitation paces exposure carefully, uses bottom-up somatic techniques, and avoids re-traumatisation through directive probing of traumatic content during the acute experience.
  4. Are couples sessions inherently riskier? Yes, when screening is insufficient. High-conflict or coercive dynamics can intensify under psilocybin. Trained facilitators with couples therapy backgrounds are essential.
  5. How often should follow-ups occur after a dosing session? At minimum within 24–72 hours (safety check), then weekly for 4–6 weeks. Booster or repeat sessions are typically not recommended within 90 days of a prior high-dose session.